HIV Positive Clinical Trial
Official title:
CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group
Verified date | December 2021 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
CCTG 594 is a controlled, unblinded, two-arm, randomized (1:1) clinical trial to evaluate the effectiveness of a clinic-based HIV ALERT specialist on improving endpoints of retention in care and maintenance of ART as compared to the current standard of care (SoC) in HIV primary care clinics.
Status | Completed |
Enrollment | 117 |
Est. completion date | November 24, 2020 |
Est. primary completion date | December 15, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - HIV-1 infection, as documented by any licensed screening antibody test, such as ELISA, and confirmed by a second antibody test, such as Western blot, or detectable plasma HIV-1 RNA at any time prior to study entry. If an ELISA or Western blot is not available, HIV infection may be documented by two HIV RNA values =2000 copies/mL, drawn at least 24 hours apart. The RNA assays must have been run at a CLIA-approved laboratory or equivalent. - 18 years of age or older. - Able to give written informed consent. - New patient to the clinic (defined as someone who has never engaged in HIV care) or a patient returning to care (defined as a patient previously seen at least once by a prescribing HIV provider who has not seen a prescribing HIV provider in the last 180 days and is not on a stable ARV regimen). - English or Spanish Speaking. - Registered to receive HIV primary care services at one of the identified CCTG-affiliated clinic, i.e. the Owen Clinic at UC San Diego Health System, Harbor-UCLA Medical Center clinic or Rand Schrader clinic at USC. Exclusion Criteria: - Unstable neurologic, psychiatric, or physical condition which, in the opinion of the investigator, would limit participation with study procedures for the duration of the study. - A level of drug or alcohol use that, in the opinion of the investigator, would preclude safe participation in the study. - Resident of nursing home or skilled facility. - Pregnant or breastfeeding. - Patient's first primary care visit (for new patients) or return to care visit (for patients returning to care) occurred > 60 days ago. |
Country | Name | City | State |
---|---|---|---|
United States | University Southern California | Los Angeles | California |
United States | University of California, San Diego | San Diego | California |
United States | Harbor-UCLA Medical Center | Torrance | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego | California HIV/AIDS Research Program, City of Long Beach Department of Health and Human Services, University of California, Los Angeles, University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Descriptive analyses | Descriptive secondary analyses comparing the two randomized groups will include:
Baseline and follow-up scores on HIV and health literacy assessments, disclosure rates, adherence, and measures of self-efficacy Number of primary care visits per year HIV RNA < 50 and <200 copies/mL at years 1 and 2 CD4 cell counts and changes from baseline in CD4 at years 1 through 2 Scores on Beck Depression Index Substance use HIV high-risk transmission behaviors Time to AIDS diagnosis or death |
Baseline to two years | |
Other | Return to Care after Primary Endpoint | Proportions of subjects that meet the primary endpoint but subsequently return to care will be compared between the randomized groups. The times between last visit and return visit will also be compared between the randomized groups. | Baseline to 2 years | |
Primary | Time to lost to follow up | The CCTG 594 primary outcome is "time to lost to follow up." Lost to follow up is defined as "no visit with a prescribing HIV provider in the last 180 days. All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not meet the primary endpoint by the time the study ends will be censored. | Baseline to Week 48 | |
Secondary | Time to initiation of ART | The CCTG 594 secondary outcome is "time to initiation of ART." All randomized subjects will be followed for a minimum of 48 weeks. Subjects that do not initiate ART will be censored at their last visit date. | Baseline to Week 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00639145 -
Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol
|
||
Completed |
NCT01152684 -
Complementary & Alternative Medicine Use in HIV+ Latinos in the US-Mexico Border
|
||
Completed |
NCT01818258 -
IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children
|
Phase 4 | |
Withdrawn |
NCT03660722 -
Bone, Inflammation, Gut and Renal Biomarkers in Antiretroviral Naïve HIV-1 Positive Subjects
|
N/A | |
Completed |
NCT01793467 -
Transplantation and the Use of Raltegravir in HIV-Infected Patients
|
N/A | |
Completed |
NCT02938377 -
Alcohol Research Consortium in HIV-Intervention Research Arm
|
Phase 4 | |
Completed |
NCT01898754 -
Oligonucleotide Ligation Assay (OLA) Resistance Study
|
N/A | |
Active, not recruiting |
NCT01365065 -
Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy
|
Phase 2 | |
Completed |
NCT00106795 -
Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS
|
N/A | |
Not yet recruiting |
NCT02404233 -
Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects
|
Phase 4 | |
Completed |
NCT01154543 -
Safety and Efficacy of Famciclovir in HIV1 Positive Adults With Recurrent Genital Herpes
|
N/A | |
Completed |
NCT01154556 -
RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice
|
N/A | |
Completed |
NCT00857350 -
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
|
N/A | |
Recruiting |
NCT01875588 -
Thinking and Memory Problems in People With HIV
|
||
Completed |
NCT01941121 -
CCTG 593: Testing and Linkage to Care
|
N/A | |
Terminated |
NCT01904201 -
Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People
|
N/A | |
Enrolling by invitation |
NCT00941889 -
The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata
|
N/A | |
Completed |
NCT03531749 -
Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate
|
N/A | |
Completed |
NCT02935296 -
Integrated Treatment and Prevention for People Who Inject Drugs
|
Phase 3 | |
Completed |
NCT01536899 -
Medical Marijuana Use in HIV+ Patients Prospective Cohort Study
|